|OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference|
|Date : 2022-03-22 View : 794|
OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference
Suwon, Republic of Korea, October 21, 2021 – OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will hold one-on-one partnering meetings at BIO-Europe Digital 2021, being held virtually October 25-28, 2021.
Sun Woo Hong, Ph.D., head of R&D at OliX Pharmaceuticals, and June Hyun Park, Ph.D., principal scientist at OliX Pharmaceuticals, will be available to discuss platform-based early discovery collaborations as well as global licensing options for the Company’s pipeline programs for OLX703A for hepatitis B virus (HBV), OLX104C for androgenic alopecia (hair loss) and OLX702A for non-alcoholic steatohepatitis (NASH).
To schedule a virtual meeting, please visit the BIO-Europe partneringONE® platform here: https://informaconnect.com/bioeurope/partnering/
|Prev||OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board|
|Next||OliX Pharmaceuticals Enters Agreement with Pharmaron|